Synecta in future CAR-T programs
This market research assesses how additional clinical superiority data for Synecta-based CAR manufacturing would change buying behavior and tests acceptance of competitive repopulation data.
Compared with CD3/CD28 beads, Synecta has shown immune synapse formation, more balanced T-cell metabolism, improved cell killing in several preclinical models, and increased persistence in a clinical trial. We now want to test in a controlled clinical study whether Synecta activation and expansion confer superiority in CAR-T fitness in cancer patients.
Competitive repopulation means two cell populations in one patient
Each patient’s cells are used to make two comparable CAR-T products, one with Synecta and one with CD3/CD28 beads. Equal numbers are mixed and infused into the same patient. Tracking both populations over approximately six months shows which persists better under the same conditions.
19 questions, shown one at a time. Open-text answers are optional.
